Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A.

Clin Transl Oncol. 2017 Jun;19(6):667-681. doi: 10.1007/s12094-016-1594-x. Epub 2016 Dec 19.

2.

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.

Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M.

Oncotarget. 2017 May 23;8(21):35289-35300. doi: 10.18632/oncotarget.13311.

3.

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.

Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E.

Virchows Arch. 2016 Nov;469(5):489-503. Epub 2016 Aug 17. Review.

4.

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.

Dietel M, Bubendorf L, Dingemans AM, Dooms C, Elmberger G, García RC, Kerr KM, Lim E, López-Ríos F, Thunnissen E, Van Schil PE, von Laffert M.

Thorax. 2016 Feb;71(2):177-84. doi: 10.1136/thoraxjnl-2014-206677. Epub 2015 Nov 3. Review.

5.

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, Biscuola M, Paz-Ares L, Hardisson D, de Castro J, Camacho MC, Rodriguez-Abreu D, Abdulkader I, Ramirez J, Reguart N, Salido M, Pijuán L, Arriola E, Sanz J, Folgueras V, Villanueva N, Gómez-Román J, Hidalgo M, López-Ríos F.

PLoS One. 2014 Sep 23;9(9):e107200. doi: 10.1371/journal.pone.0107200. eCollection 2014.

6.

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.

Estévez LG, Suarez-Gauthier A, García E, Miró C, Calvo I, Fernández-Abad M, Herrero M, Marcos M, Márquez C, Lopez Ríos F, Perea S, Hidalgo M.

Breast Cancer Res. 2014 Sep 4;16(4):R76. doi: 10.1186/bcr3695.

7.

Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M.

Br J Cancer. 2014 Oct 14;111(8):1677-8. doi: 10.1038/bjc.2014.129. Epub 2014 Mar 18. No abstract available.

8.

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.

Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, Valencia A, Sidransky D, Hidalgo M.

Clin Cancer Res. 2014 May 1;20(9):2476-84. doi: 10.1158/1078-0432.CCR-13-3047. Epub 2014 Mar 14.

9.

MicroRNA-dependent regulation of transcription in non-small cell lung cancer.

Molina-Pinelo S, Gutiérrez G, Pastor MD, Hergueta M, Moreno-Bueno G, García-Carbonero R, Nogal A, Suárez R, Salinas A, Pozo-Rodríguez F, Lopez-Rios F, Agulló-Ortuño MT, Ferrer I, Perpiñá A, Palacios J, Carnero A, Paz-Ares L.

PLoS One. 2014 Mar 13;9(3):e90524. doi: 10.1371/journal.pone.0090524. eCollection 2014.

10.

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M.

Br J Cancer. 2013 Aug 20;109(4):926-33. doi: 10.1038/bjc.2013.415. Epub 2013 Aug 1.

11.

Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.

Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Tsai J, Vaks J, Current R, Lawrence HJ, Gonzalez de Castro D.

J Clin Pathol. 2013 May;66(5):381-5. doi: 10.1136/jclinpath-2012-201240. Epub 2013 Feb 5.

12.

Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers.

Conde E, Angulo B, Izquierdo E, Paz-Ares L, Belda-Iniesta C, Hidalgo M, López-Ríos F.

Clin Transl Oncol. 2013 Jul;15(7):503-8. doi: 10.1007/s12094-012-0983-z. Epub 2013 Jan 29.

13.

Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.

Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Vaks J, Langland R, Lawrence HJ, de Castro DG.

PLoS One. 2013;8(1):e53733. doi: 10.1371/journal.pone.0053733. Epub 2013 Jan 10.

14.

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.

Estevez-Garcia P, Castaño A, Martin AC, Lopez-Rios F, Iglesias J, Muñoz-Galván S, Lopez-Calderero I, Molina-Pinelo S, Pastor MD, Carnero A, Paz-Ares L, Garcia-Carbonero R.

BMC Cancer. 2012 Nov 12;12:514. doi: 10.1186/1471-2407-12-514.

15.

A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.

Angulo B, Conde E, Suárez-Gauthier A, Plaza C, Martínez R, Redondo P, Izquierdo E, Rubio-Viqueira B, Paz-Ares L, Hidalgo M, López-Ríos F.

PLoS One. 2012;7(8):e43842. doi: 10.1371/journal.pone.0043842. Epub 2012 Aug 27.

16.

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.

Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca F, Rossi G.

Virchows Arch. 2012 Sep;461(3):245-57. doi: 10.1007/s00428-012-1281-4. Epub 2012 Jul 24. Review.

17.

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens.

Gonzalez de Castro D, Angulo B, Gomez B, Mair D, Martinez R, Suarez-Gauthier A, Shieh F, Velez M, Brophy VH, Lawrence HJ, Lopez-Rios F.

Br J Cancer. 2012 Jul 10;107(2):345-51. doi: 10.1038/bjc.2012.259. Epub 2012 Jun 19.

18.

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer.

Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodríguez-Peralto JL, Hidalgo M, López-Ríos F.

J Clin Pathol. 2012 Aug;65(8):751-7. doi: 10.1136/jclinpath-2012-200774. Epub 2012 May 8.

19.

Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.

García-García E, Gómez-Martín C, Angulo B, Conde E, Suárez-Gauthier A, Adrados M, Perna C, Rodríguez-Peralto JL, Hidalgo M, López-Ríos F.

Histopathology. 2011 Jul;59(1):8-17. doi: 10.1111/j.1365-2559.2011.03894.x.

20.

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.

Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjö A, Gorgoulis V, Höfler G, Jung A, Kotsinas A, Laurent-Puig P, López-Ríos F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E.

Oncologist. 2011;16(4):467-78. doi: 10.1634/theoncologist.2010-0429. Epub 2011 Mar 26.

Supplemental Content

Loading ...
Support Center